- Home
- AXIL vs RADX Comparison
AXIL vs RADX Comparison
Compare AXIL & RADX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXIL
- RADX
- Stock Information
- Founded
- AXIL 2015
- RADX 2021
- Country
- AXIL United States
- RADX Australia
- Employees
- AXIL N/A
- RADX N/A
- Industry
- AXIL Package Goods/Cosmetics
- RADX
- Sector
- AXIL Consumer Discretionary
- RADX
- Exchange
- AXIL Nasdaq
- RADX NYSE
- Market Cap
- AXIL 29.2M
- RADX 31.8M
- IPO Year
- AXIL N/A
- RADX N/A
- Fundamental
- Price
- AXIL $5.80
- RADX $4.05
- Analyst Decision
- AXIL
- RADX Strong Buy
- Analyst Count
- AXIL 0
- RADX 1
- Target Price
- AXIL N/A
- RADX $15.00
- AVG Volume (30 Days)
- AXIL 18.7K
- RADX 37.7K
- Earning Date
- AXIL 04-08-2025
- RADX 02-26-2025
- Dividend Yield
- AXIL N/A
- RADX N/A
- EPS Growth
- AXIL 93.65
- RADX N/A
- EPS
- AXIL 0.29
- RADX N/A
- Revenue
- AXIL $27,007,463.00
- RADX $204,609.00
- Revenue This Year
- AXIL N/A
- RADX N/A
- Revenue Next Year
- AXIL N/A
- RADX N/A
- P/E Ratio
- AXIL $20.85
- RADX N/A
- Revenue Growth
- AXIL N/A
- RADX N/A
- 52 Week Low
- AXIL $3.54
- RADX $3.50
- 52 Week High
- AXIL $12.90
- RADX $50.82
- Technical
- Relative Strength Index (RSI)
- AXIL 49.83
- RADX N/A
- Support Level
- AXIL $5.00
- RADX N/A
- Resistance Level
- AXIL $6.69
- RADX N/A
- Average True Range (ATR)
- AXIL 1.04
- RADX 0.00
- MACD
- AXIL 0.16
- RADX 0.00
- Stochastic Oscillator
- AXIL 61.11
- RADX 0.00
About AXIL AXIL Brands Inc. Common Stock
AXIL Brands Inc is a company which is is a manufacturer and marketer of premium hearing enhancement and protection products, including ear plugs, earmuffs, and ear buds, under the AXIL brand. AXIL delivers top hearing enhancement, protection, & audio devices. From ultra comfortable fitting processes, to stereo quality sound performance, to reliable & durable engineering.
About RADX RADIOPHARM THERANOSTICS LIMITED SPON ADS EACH REP 300 ORD
Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.